Testing Natrunix Combined with Methotrexate for Rheumatoid Arthritis
This study tested whether adding an investigational drug called Natrunix to the standard RA medication methotrexate (plus folate) is safe and more effective than methotrexate with a placebo. It was a randomized, double-blind, placebo-controlled trial, meaning participants were assigned by chance to one of the two groups, and neither participants nor study staff knew which […]
Using a Molecular Test to Guide Treatment Choice for Rheumatoid Arthritis
This study tested a new molecular tool (called a “response classifier”) that analyzes a patient’s biology to predict which type of medication — a JAK inhibitor, T-cell inhibitor, or IL-6 inhibitor — is most likely to work for them. The goal was to move toward more personalized treatment for rheumatoid arthritis, rather than a one-size-fits-all […]
Continued Secukinumab Treatment for Prior Novartis Study Participants
This open-label, long-term extension study allowed patients who had already completed a previous Novartis-sponsored secukinumab study to continue receiving secukinumab treatment if their doctor believed they would benefit from it. Participants were monitored for ongoing safety and tolerability. This type of study helps researchers understand the long-term effects of a medication. Condition: Various (per prior […]
V Secukinumab Safety Study for Giant Cell Arteritis or Polymyalgia Rheumatica
This open-label study (meaning all participants knew which treatment they received) examined how a medication called secukinumab behaves in the body when given through an IV infusion (directly into a vein) in adults with Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR). Researchers looked at how quickly the drug is absorbed and cleared, as well […]
Testing a New Combination Treatment for Gout
This study evaluated whether an investigational drug called D-0120, taken together with the standard gout medication allopurinol, is safe and effective for people living with gout. Participants were randomly assigned to receive either the combination treatment or a placebo. The study aimed to find out if adding D-0120 to allopurinol reduces gout symptoms better than […]
Testing a New Treatment (LY3871801) for Moderate-to-Severe Rheumatoid Arthritis
This study tested whether an investigational drug called LY3871801 is safe and effective for adults with moderately to severely active rheumatoid arthritis. It was a randomized, double-blind study, meaning participants were assigned by chance to receive either the study drug or a placebo (an inactive look-alike), and neither participants nor study staff knew which was […]
Blood Sample Study for Rheumatoid Arthritis Patients Starting a New Medication
This study collected blood samples from adults with rheumatoid arthritis (RA) who were not responding well — or could not tolerate — their current disease-modifying medication and were starting a new biologic or targeted treatment. The goal was to better understand how these treatments work in real patients over time. No experimental drug was given; […]
Testing LY2439821 for Moderate-to-Severe Plaque Psoriasis
This multicenter study is evaluating the effectiveness and safety of an investigational drug called LY2439821 in Chinese patients with moderate-to-severe plaque psoriasis, a chronic skin condition that causes red, scaly patches. The study includes an initial treatment phase where participants are randomly assigned to the drug or placebo (double-blind), followed by a maintenance phase to […]
Testing Nipocalimab for Moderate-to-Severe Sjögren’s Disease
This Phase 3 study is evaluating whether an investigational drug called nipocalimab can safely and effectively reduce symptoms in adults with moderate to severe Sjögren’s disease. Participants are randomly assigned to receive either nipocalimab or a placebo. The study is conducted at multiple sites and is fully blinded — neither participants nor study staff know […]
Phase 3 Study of AR882 for Gout
This Phase 3 study is testing whether an investigational drug called AR882 is safe and effective for people with gout. Participants are randomly assigned to receive either AR882 or a placebo (a look-alike with no active ingredient). The study is double-blind and takes place at multiple research sites. Gout is a painful form of inflammatory […]